Search

Your search keyword '"Pujari, Pramod"' showing total 19 results
Start Over Author "Pujari, Pramod"
19 results on '"Pujari, Pramod"'

1. A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants

Author

Sharma, Hitt, Parekh, Sameer, Pujari, Pramod, Shewale, Sunil, Desai, Shivani, Kawade, Anand, Lalwani, Sanjay, Ravi, M. D., Kamath, Veena, Mahopatra, Jagannath, Kulkarni, Ganesh, Tayade, Deepak, Ramanan, Padmasani Venkat, Uttam, Kheya Ghosh, Rawal, Lalit, Gawande, Avinash, Kumar, N. Ravi, Tiple, Nishikant, Vagha, Jayant, Thakkar, Pareshkumar, Khandgave, Prashant, Deshmukh, Bhaskar Jedhe, Agarwal, Anurag, Dogar, Vikas, Gautam, Manish, Jaganathan, K. S., Kumar, Rakesh, Sharma, Inderjit, and Gairola, Sunil

Published
2024
Full Text
View/download PDF

2. A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers

Author

Sharma, Hitt, Parekh, Sameer, Pujari, Pramod, Shewale, Sunil, Desai, Shivani, Kawade, Anand, Lalwani, Sanjay, Ravi, M.D., Ramanan, Padmasani Venkat, Kamath, Veena, Agarwal, Anurag, Dogar, Vikas, Gautam, Manish, Jaganathan, K.S., Kumar, Rakesh, Sharma, Inderjit, and Gairola, Sunil

Published
2024
Full Text
View/download PDF

3. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial

Author

Sharma, Hitt, Parekh, Sameer, Pujari, Pramod, Shewale, Sunil, Desai, Shivani, Bhatla, Neerja, Joshi, Smita, Pimple, Sharmila, Kawade, Anand, Balasubramani, Latha, Thomas, Anitha, Suri, Vanita, Lalwani, Sanjay, Uday, Rajini, Kamath, Veena, Mandal, Ranajit, Rajeswar, A, Peedicayil, Abraham, Poli, Usha Rani, Banerjee, Dipanwita, Sankaranarayanan, Rengaswamy, Basu, Partha, Muwonge, Richard, Gairola, Sunil, Dogar, Vikas, Rao, Harish, and Shaligram, Umesh

Published
2023
Full Text
View/download PDF

5. Sub-Acute Toxicity Study of Hydro-Alcoholic Extracts of Sansevieria cylindrica and Plumeria obtusa in Wistar Albino Rats

Author

Shewale, Sunil, primary, Undale, Vaishali, additional, Addepalli, V., additional, Bhalchim, Vrushali, additional, Desai, Shivani, additional, Wawale, Vikas, additional, Shelar, Maruti, additional, Padole, Shubham, additional, Satone, Shital, additional, Lembhe, Shweta, additional, Parekh, Sameer, additional, and Pujari, Pramod, additional

Published
2023
Full Text
View/download PDF

6. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4–65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany

Author

Aydin, Inci, primary, May, Marcus, additional, Pisano, Fabio, additional, Mpofu-Maetzig, Nontsikelelo, additional, Grode, Leander, additional, Parekh, Sameer, additional, Pujari, Pramod, additional, Shewale, Sunil, additional, Desai, Shivani, additional, Sharma, Hitt, additional, Rao, Harish, additional, Gautam, Manish, additional, Gairola, Sunil, additional, and Shaligram, Umesh, additional

Published
2023
Full Text
View/download PDF

8. A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants.

Author

Sharma, Hitt, Parekh, Sameer, Pujari, Pramod, Shewale, Sunil, Desai, Shivani, Kawade, Anand, Lalwani, Sanjay, Ravi, M. D., Kamath, Veena, Mahopatra, Jagannath, Kulkarni, Ganesh, Tayade, Deepak, Ramanan, Padmasani Venkat, Uttam, Kheya Ghosh, Rawal, Lalit, Gawande, Avinash, Kumar, N. Ravi, Tiple, Nishikant, Vagha, Jayant, and Thakkar, Pareshkumar

Subjects
VACCINE immunogenicity, THERAPEUTIC equivalency in drugs, INFANTS, HAEMOPHILUS influenzae, HEPATITIS B, WHOOPING cough
Abstract

A fully liquid hexavalent containing Diphtheria (D), Tetanus (T) toxoids, whole cell Pertussis (wP), Hepatitis B (Hep B), type 1, 2, 3 of inactivated poliovirus (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (DTwP-HepB-IPV-Hib vaccine, HEXASIIL®) was tested for lot-to-lot consistency and non-inferiority against licensed DTwP-HepB-Hib + IPV in an open label, randomized Phase II/III study. In Phase III part, healthy infants received DTwP-HepB-IPV-Hib or DTwP-HepB-Hib + IPV vaccines at 6, 10 and 14 weeks of age. Blood samples were collected prior to the first dose and 28 days, post dose 3. Non inferiority versus DTwP-HepB-Hib + IPV was demonstrated with 95% CIs for the treatment difference for seroprotection/seroconversion rates. For DTwP-HepB-IPV-Hib lots, limits of 95% CI for post-vaccination geometric mean concentration ratios were within equivalence limits (0.5 and 2). Vaccine was well-tolerated and no safety concerns observed. Clinical Trial Registration – CTRI/2019/11/022052 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactin

Author

Rathod, Vishal, primary, Kadam, Laxmikant, additional, Gautam, Manish, additional, Gumma, Prabhu Dasu, additional, Marke, Kevin, additional, Asokanathan, Cathy, additional, Douglas-Bardsley, Alex, additional, Hassell, Laura, additional, Bhandare, Sachin, additional, Gupta, Sumit, additional, Parekh, Sameer, additional, Pujari, Pramod, additional, Rao, Harish, additional, Sharma, Hitt, additional, Shaligram, Umesh, additional, and Gairola, Sunil, additional

Published
2023
Full Text
View/download PDF

10. A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults

Author

Sharma, Hitt, primary, Anil, K., additional, Parekh, Sameer, additional, Pujari, Pramod, additional, Shewale, Sunil, additional, Desai, Shivani, additional, Madhusudhan, R.L., additional, Patel, Jaya, additional, Eswaraiah, Anand, additional, Rao, Harish, additional, Gairola, Sunil, additional, and Shaligram, Umesh, additional

Published
2023
Full Text
View/download PDF

11. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India

Author

Sharma, Hitt J, primary, Parekh, Sameer, additional, Pujari, Pramod, additional, Shewale, Sunil, additional, Desai, Shivani, additional, Kawade, Anand, additional, Ravi, Mandyam, additional, Oswal, Jitendra, additional, James, Saji, additional, Mahantashetti, N., additional, Munshi, Renuka, additional, Ghosh, Apurba, additional, Rao, Venkateshwar, additional, Balsubramaniam, Sundaram, additional, Varughese, P., additional, Somshekhar, A., additional, Ginsburg, Amy Sarah, additional, Rao, Harish, additional, Gautam, Manish, additional, Gairola, Sunil, additional, and Shaligram, Umesh, additional

Published
2023
Full Text
View/download PDF

12. A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months

Author

Sharma, Hitt, primary, Lalwani, Sanjay, additional, Parekh, Sameer, additional, Pujari, Pramod, additional, Shewale, Sunil, additional, Palkar, Sonali, additional, Hanumante, Neeta, additional, Gokhale, Shilpa, additional, Ks, Jaganathan, additional, Kumar, Rakesh, additional, Sharma, Inderjit, additional, and Gairola, Sunil, additional

Published
2022
Full Text
View/download PDF

18. Vaccines For Type 1 Diabetes: Prevention or Reversal?

Author

Desai, Shivani, Buchade, Shubhangi, Chitlange, Sohan, Sharma, Hitt, Bhombe, Dhiraj, Shewale, Sunil, and Pujari, Pramod

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disease which leads to the destruction of pancreatic β-cells, thereby causing insufficient insulin production. Globally, around 98, 200 children and adolescents below 15 years of age and almost 128,900 subjects below 20 years of age develop T1DM annually, along with severe complications deteriorating their quality of life. In India alone, around 15,900 incident cases below 15 years have reported annually. Hence, its prevention and reversal are significant. Unlike other chronic diseases, T1DM involves the presence of various autoantigens, which can be targeted by proper immunisation. The development of reliable immuno-regulatory surrogate markers would be of great benefit. Vaccines can be one of such strategies in the journey to prevent T1DM. It would not only benefit greatly to reduce the sufferings caused due to diabetic complications but could also help to reverse T1DM, by modulating the autoantigenic immunological reactions and prevent further degradation of pancreatic β-cells. This review collates a wide range of information related to the vaccine studies conducted in animal and human models to prevent and reverse T1DM.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results